In an article published in the May 2025 edition of the CPI Antitrust Chronicle, Partner Nana Wilberforce and Counsel John O’Toole and Sarah Pugh offer predictions about the areas incoming regulators may prioritize in their antitrust enforcement agendas for healthcare.
Click here to continue reading . . .
WilmerHale lawyer Ali Jessani recently authored the article “Health Privacy in 2025 and Beyond,” published by the American Bar Association.
Data Protection law in the United States has evolved rapidly over the past few years. The changes relating to health privacy have been particularly noteworthy. Gone are the days where companies only needed to worry about whether they fall under the purview of HIPAA. Now, almost all health data (as well as data that could potentially […]
The Medicaid Drug Rebate Program (MDRP) is a cornerstone of pharmaceutical pricing regulation, requiring drug manufacturers to provide rebates to Medicaid in exchange for coverage of their products. Established under the Omnibus Budget Reconciliation Act of 1990 (OBRA ’90) and administered by the Centers for Medicare & Medicaid Services (CMS), the MDRP ensures Medicaid programs pay competitive prices for prescription drugs while presenting compliance challenges for manufacturers.
Given the strict reporting requirements, complex rebate calculations, […]